Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Otilimab in Moderate to Severe Rheumatoid Arthritis (contRAst 1)
NCT03980483Phase 3Completed
- Sponsor
- GSK
- Start
- May 2019
- Primary completion
- Sep 2021
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial of otilimab in rheumatoid arthritis (RA) (6 arms), sponsored by GSK. Primary endpoint: American College of Rheumatology 20% Improvement at 12 weeks. Started May 2019; status: completed.
02
Drugs
otilimab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT03980483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03980483.